Publications by authors named "Masaya Arikawa"

Article Synopsis
  • A study investigated the effects of high-risk coronary artery plaques on late luminal narrowing and clinical events in patients after percutaneous coronary intervention.
  • Over one year, the coronary artery lumen area decreased notably, especially in specific types of plaques, such as thin-cap and thick-cap fibroatheromas.
  • Thin-cap fibroatheroma presence was linked to a higher risk of needing further revascularization procedures after ischemia, while no significant connection was found between coronary artery calcium levels and clinical outcomes within three years.
View Article and Find Full Text PDF

We recently reported that troglitazone, an insulin-sensitizing agent, inhibited l-type Ca current (ICa,L) more effectively in streptozotocin (STZ)-induced diabetic ventricular myocytes than in age-matched control myocytes. However, whether this agent would effectively inhibit ICa,L in an animal model of hyperinsulinemia is unknown. Using whole-cell voltage-clamp techniques, ICa,L was measured in ventricular myocytes isolated from 12 to 16 weeks on fructose-enriched feeding and age-matched control rats.

View Article and Find Full Text PDF

The present study investigated the role of translocation of protein kinase C (PKC) during ischemia/reperfusion in cardioprotection in the streptozotocin (STZ)-induced diabetic rat. Twelve weeks after injection of STZ or vehicle, male Wister-King rat hearts were isolated and perfused in the presence or absence of 50 nmol/L staurosporine or 2 mumol/L chelerythrine using a Langendorff apparatus. Thirty minutes of global ischemia was followed by the same period of reperfusion.

View Article and Find Full Text PDF

1. Troglitazone, an insulin-sensitizing agent shown to improve cardiac function in both experimental animals and patients with diabetes, inhibits voltage-dependent L-type Ca(2+) currents (I(Ca,L)) in cardiac myocytes, which may underlie its cardioprotective effects. However, inhibition by troglitazone of I(Ca,L) in diabetic cardiac myocytes has not been characterized.

View Article and Find Full Text PDF